MIPS-eligible clinicians should review their scores to confirm performance. Any scoring concerns can be addressed through a targeted review
Search results for: liver
A New Treatment for Fibromyalgia?
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
How ACR Volunteers Educate School Nurses About Childhood-Onset Lupus
The ACR’s SHOP initiative partners pediatric rheumatologists & school nurses to raise cSLE awareness & better support students living with lupus.
President’s Corner: ACR/ARP Education That Fits
Fulfill your lifelong learning goals with the ACR & ARP. Explore diverse educational options, including journals, podcasts & ACR Convergence 2025.
AMA State Advocacy Roundtable Addresses Pressing Policy Challenges
The roundtable included discussions on emerging issues in state advocacy, prior authorization reform, likely impacts of the Big Beautiful Bill and physician wellness.
ACR President Warns: Access to Care Is at Risk Without Medicare Payment Reform
In a recent commentary published by Medscape, ACR President Carol Langford, MD, MHS, issues a stark warning: If Congress does not reform the physician payment system, patients may face increasing difficulty accessing essential medical services.
Celebrating Interdisciplinary Collaboration: Pathways to Success
Four past ARP presidents mark the organization’s 60th anniversary by examining its evolution alongside significant challenges & opportunities in the field.
A Sound Diagnosis for Glandular Swelling
In this case study, ultrasonography proves useful for excluding a diagnosis of Sjögren’s disease, leading to a correct diagnosis of IgG4-RD.
White Bagging: A ‘Prescription for Disruption’ in Rheumatologic Care
In a recent op-ed published by MedCity News, rheumatologist and ACR Insurance Subcommittee Chair Michael Feely, MD, delivers a powerful critique of the insurance practice known as white bagging, calling it a “prescription for disruption” that threatens the quality and timeliness of patient care.
Lowest Price, Highest Risk? New Drug Policy’s Potential Effect on Rheumatology
On July 31, President Trump sent formal letters to the CEOs of 17 major pharmaceutical companies, laying out several requirements the companies must meet within 60 days or face unspecified consequences. These include Most-Favored-Nation pricing for Medicare, Medicaid and private markets.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 127
- Next Page »